Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

J&J Reaches Deal With FDA to Revive Sedasys Device Application

Johnson & Johnson, the world’s second-biggest seller of health products, reached an agreement with U.S. regulators to reopen its application for the Sedasys sedation system for endoscopy patients.

The company said it withdrew an appeal of the Food and Drug Administration’s April 2010 denial of the Sedasys application because of the agreement. An FDA advisory panel was scheduled to meet Dec. 14 on the appeal.

Sedasys is a computer-assisted system that administers propofol for patients being screened for colorectal cancer or undergoing upper gastrointestinal procedures. A trial showed patients who used Sedasys had a lower risk of over-sedation than those given benzodiazepine and opioids, New Brunswick, New Jersey-based J&J said.

“We’ve worked cooperatively with the FDA in recent months to address the agency’s concerns and we’re optimistic that we now have a path forward that will allow us to bring this important innovation to market,” Karen Licitra, company group chairwoman and worldwide franchise chairwoman for J&J subsidiary Ethicon Endo-Surgery Inc., said today in a statement.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.